Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
$49.08
-2.3%
$45.88
$21.72
$51.86
$9.60B1.232.94 million shs1.49 million shs
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$17.89
+2.3%
$15.08
$8.02
$18.08
$8.69B1.666.56 million shs6.72 million shs
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
$33.75
+0.5%
$29.78
$17.82
$34.55
$2.49B0.14705,288 shs356,168 shs
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
$105.56
+0.1%
$100.91
$24.50
$105.85
$8.63B0.121.76 million shs974,700 shs
10 Best Stocks to Own: Fall 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
-2.29%-4.36%+6.26%+47.21%+92.02%
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
+2.22%-0.43%+19.17%+41.30%+20.41%
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
+0.51%+1.11%+24.45%+25.51%+27.70%
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
+0.10%+0.28%+0.58%+40.63%+277.13%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
4.6759 of 5 stars
4.52.00.03.92.63.30.6
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
3.0847 of 5 stars
2.42.00.00.33.31.71.3
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
2.682 of 5 stars
2.53.00.00.03.43.30.6
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
2.4038 of 5 stars
2.15.00.00.02.62.50.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
3.00
Buy$61.3525.01% Upside
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
2.78
Moderate Buy$17.33-3.13% Downside
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
3.00
Buy$41.1721.98% Upside
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
2.14
Hold$109.003.26% Upside

Current Analyst Ratings Breakdown

Latest KNSA, BBIO, VRNA, and ELAN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/20/2025
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
Zacks Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
8/11/2025
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$12.00 ➝ $18.00
8/8/2025
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$18.00 ➝ $19.00
8/8/2025
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
Zacks Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold
8/6/2025
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetSector Outperform ➝ Sector Outperform$55.00 ➝ $57.00
8/6/2025
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$60.00 ➝ $61.00
7/30/2025
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
Raymond James Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$56.00
7/29/2025
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$95.00
7/29/2025
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$45.00 ➝ $54.00
7/23/2025
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$17.00 ➝ $18.00
7/21/2025
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$66.00
(Data available from 8/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
$235.81M39.79N/AN/A($9.30) per share-5.28
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$4.44B2.00$2.31 per share7.76$13.64 per share1.31
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
$529.33M4.73N/AN/A$6.68 per share5.05
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
$221.67M38.97N/AN/A$3.27 per share32.28
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
-$535.76M-$4.09N/AN/AN/A-329.25%N/A-85.69%11/11/2025 (Estimated)
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$338M$0.8620.8120.103.259.68%7.04%3.45%11/6/2025 (Estimated)
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
-$43.19M$0.04843.96135.00N/A0.90%1.05%0.80%11/4/2025 (Estimated)
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
-$173.42M-$0.99N/A3,518.67N/A-36.62%-21.12%-9.07%11/3/2025 (Estimated)

Latest KNSA, BBIO, VRNA, and ELAN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/7/2025Q2 2025
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$0.1989$0.26+$0.0611$0.02$1.19 billion$1.24 billion
8/6/2025Q2 2025
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
-$0.01$0.13+$0.14$0.13$90.41 million$103.14 million
8/5/2025Q2 2025
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
-$0.83-$0.95-$0.12-$0.95$98.46 million$110.57 million
7/29/2025Q2 2025
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
$0.18$0.23+$0.05$0.23$145.21 million$156.80 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
N/AN/AN/AN/AN/A
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
N/AN/AN/AN/AN/A
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
N/AN/AN/AN/AN/A
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
N/A
5.19
5.08
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
0.61
2.60
1.40
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
N/A
3.57
3.16
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
0.87
10.71
10.54
CompanyEmployeesShares OutstandingFree FloatOptionable
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
400191.17 million156.38 millionOptionable
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
9,000496.81 million492.39 millionOptionable
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
22074.11 million34.48 millionOptionable
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
3081.83 million81.05 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

BridgeBio Pharma stock logo

BridgeBio Pharma NASDAQ:BBIO

$49.08 -1.15 (-2.29%)
Closing price 08/22/2025 04:00 PM Eastern
Extended Trading
$49.52 +0.45 (+0.91%)
As of 08/22/2025 07:32 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.

Elanco Animal Health stock logo

Elanco Animal Health NYSE:ELAN

$17.89 +0.40 (+2.30%)
Closing price 08/22/2025 03:59 PM Eastern
Extended Trading
$17.85 -0.04 (-0.23%)
As of 08/22/2025 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.

Kiniksa Pharmaceuticals International stock logo

Kiniksa Pharmaceuticals International NASDAQ:KNSA

$33.75 +0.17 (+0.51%)
Closing price 08/22/2025 04:00 PM Eastern
Extended Trading
$33.44 -0.31 (-0.92%)
As of 08/22/2025 07:05 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. The company was incorporated in 2015 and is based in Hamilton, Bermuda.

Verona Pharma PLC American Depositary Share stock logo

Verona Pharma PLC American Depositary Share NASDAQ:VRNA

$105.56 +0.11 (+0.10%)
Closing price 08/22/2025 04:00 PM Eastern
Extended Trading
$105.56 0.00 (0.00%)
As of 08/22/2025 07:27 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. The company was incorporated in 2005 and is headquartered in London, the United Kingdom.